TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF)(TSX:BVF) responded today to various media and shareholder enquiries relating to the recent BVF-033 Non-Approval Letter from the U.S. Food & Drug Administration (FDA), which was disclosed by Biovail on July 20, 2007. Biovail remains committed to securing the approval of BVF-033, which would allow the Company to move forward with the development and commercial launch of BVF-045 – a combination product incorporating BVF-033 with an undisclosed anti-depressant agent.
